Europe Clinical Trial Imaging Market Forecast to 2028 -Regional Analysis

The Europe clinical trial imaging market is expected to grow from US$ 501.22 million in 2023 to US$ 705.65 million by 2028; it is estimated to register a CAGR of 7.1% from 2023 to 2028.

Accelerated Clinical Trial Activities in Pharmaceutical and Biotechnology Industries Fuels Europe Clinical Trial Imaging Market

The ultimate goal of drug development is to bring new compounds with proven therapeutic effects to the market. Obtaining accurate information on conducted trials' outcomes poses a significant challenge in estimating the success rate of clinical trials, as collecting such data is expensive, time-consuming, and prone to errors. In-vivo imaging performed on human subjects in clinical trials are likely to improve the success rate of the drug development process. For example, positron emission tomography (PET) imaging can visualize radio-labeled compounds that are intended for targeted drugs in-vivo activities or monitor compound tissue exposure during clinical trial testing. Other in-vivo imaging techniques, such as magnetic resonance imaging (MRI), efficiently visualize human anatomy with the capability to visualize drug molecules in the body of clinical trial participants capable of detecting adequate sensitivity and specificity. Mass spectrometry imaging (MSI) is currently utilized to visualize drug molecules for ex-vivo tissue sections. Therefore, the increasing use of imaging techniques or modalities for clinical trial testing to determine clinical dose efficacy and toxicity leads to greater success rates of clinical trials, which, in turn, is favoring the growth of the Europe clinical trial imaging market.

Europe Clinical Trial Imaging Market Overview

The Europe clinical trial imaging market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Rise in the number of clinical trial activities for new drug development and innovative product launches by the service provider companies are a few factors likely to support the market growth in Europe during the forecast period. Further, cancer, cardiovascular illness, nervous system disorders, and infectious diseases are the most frequently studied conditions in clinical trials in Germany. Clinical research benefits from Germany's well-established infrastructure for transport, communication, energy, and public services, along with the large patient pool and high demand for quality healthcare. Coordinating centers for clinical trials were established as part of a new funding program under the Federal Ministry of Education and Research to strengthen academic clinical research. Therefore, Germany's clinical trial approval processes are standardized, reliable, transparent, and approved for relatively short study start-up timelines. Further, in Germany, top CROs provide clinical trial imaging software for imaging studies. Pharmtrace, a Berlin-based CRO's "ERICA," provides a flexible platform for clinical trial image management combining regulatory compliance for the collection, centralization, and QC of clinical trial medical images. ERICA was developed and validated by pharmtrace intended for real-life clinical trials to document and make clinical imaging GCP-compliant correctly.

Exhibit: Europe Clinical Trial Imaging Market Revenue and Forecast to 2028 (US$ Million)

Europe Clinical Trial Imaging Market Segmentation

The Europe clinical trial imaging market is segmented on the basis of modality, offering, end user, and country.

Based on modality, the Europe clinical trial imaging market is segmented into tomography, magnetic resonance imaging (MRI), ultrasound, positron emission tomography (PET), X-ray, echocardiography, and others. The tomography segment registered the largest market share in 2023.

Based on offering, the Europe clinical trial imaging market is segmented into operational imaging services, imaging software, read analysis services, trial design and consulting services, and others. The operational imaging services segment held the largest market share in 2023.

Based on end user, the Europe clinical trial imaging market is segmented into contract research organizations (CROs), pharmaceutical and biotechnology companies, academic and research institutes, and others. The contract research organizations (CROs) segment held the largest market share in 2023.

Based on country, the market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the market share in 2023.

Calyx Inc, eResearch Technology Inc, ICON PLC, IXICO plc, Medical Metrics Inc, VIDA Diagnostics Inc, and WCG Clinical Inc are the leading companies operating in the Europe clinical trial imaging market.